Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DpdtaA-Cu is a copper(II) chelate of the dithiocarbamate derivative di-2-pyridylhydrazone dithiocarbamate s-acetic acid (DpdtaA). It is an experimental small molecule investigated for its antiproliferative effects against hepatocellular carcinoma. The compound's mechanism of action involves the generation of reactive oxygen species (ROS) and the upregulation of the p53 tumor suppressor protein, partially by disrupting the interaction between p53 and its negative regulator, Mdm2. This leads to the induction of intrinsic apoptosis and autophagy. Research has shown that the formation of the copper complex (DpdtaA-Cu) significantly attenuates the antiproliferative potency compared to the free ligand DpdtaA, although the fundamental apoptotic mechanisms remain consistent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DpdtaA-Cu.